Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C18H14F3N5O3S2 |
| Molecular Weight | 469.461 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1(C)N(C(=S)N(C1=O)C2=CC=C(C#N)C(=C2)C(F)(F)F)C3=CC=CC(=N3)S(N)(=O)=O
InChI
InChIKey=JIIHFLNYGVNTFP-UHFFFAOYSA-N
InChI=1S/C18H14F3N5O3S2/c1-17(2)15(27)25(11-7-6-10(9-22)12(8-11)18(19,20)21)16(30)26(17)13-4-3-5-14(24-13)31(23,28)29/h3-8H,1-2H3,(H2,23,28,29)
| Molecular Formula | C18H14F3N5O3S2 |
| Molecular Weight | 469.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291. | 2011-09 |
|
| Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer. | 2010-12-01 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:51:11 GMT 2025
by
admin
on
Mon Mar 31 21:51:11 GMT 2025
|
| Record UNII |
A5ZX7J376H
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1043446-39-4
Created by
admin on Mon Mar 31 21:51:11 GMT 2025 , Edited by admin on Mon Mar 31 21:51:11 GMT 2025
|
PRIMARY | |||
|
44462785
Created by
admin on Mon Mar 31 21:51:11 GMT 2025 , Edited by admin on Mon Mar 31 21:51:11 GMT 2025
|
PRIMARY | |||
|
A5ZX7J376H
Created by
admin on Mon Mar 31 21:51:11 GMT 2025 , Edited by admin on Mon Mar 31 21:51:11 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |